Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, raised $11.2 million by offering 1.4 million units at $8, the low end of the range of $8 to $10. Existing shareholders bought $3.4 million of the IPO (30%). Each unit consisted of one share of common stock and one warrant to purchase one half of a share at an exercise price of $8.40 per whole share. Entera Bio plans to list on the Nasdaq under the symbol ENTX. Maxim Group LLC acted as a lead manager on the deal.
Entera launched its IPO with warrants attached; as such, we do not include Entera Bio in our IPO stats.
